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Abstract
BACKGROUND—The genes underlying the risk of stroke in the general population remain
undetermined.
METHODS—We carried out an analysis of genomewide association data generated from four large
cohorts composing the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium,
including 19,602 white persons (mean [±SD] age, 63±8 years) in whom 1544 incident strokes (1164
ischemic strokes) developed over an average follow-up of 11 years. We tested the markers most
strongly associated with stroke in a replication cohort of 2430 black persons with 215 incident strokes
(191 ischemic strokes), another cohort of 574 black persons with 85 incident strokes (68 ischemic
strokes), and 652 Dutch persons with ischemic stroke and 3613 unaffected persons.
RESULTS—Two intergenic single-nucleotide polymorphisms on chromosome 12p13 and within
11 kb of the gene NINJ2 were associated with stroke (P<5×10−8). NINJ2 encodes an adhesion
molecule expressed in glia and shows increased expression after nerve injury. Direct genotyping
showed that rs12425791 was associated with an increased risk of total (i.e., all types) and ischemic
stroke, with hazard ratios of 1.30 (95% confidence interval [CI], 1.19 to 1.42) and 1.33 (95% CI,
1.21 to 1.47), respectively, yielding population attributable risks of 11% and 12% in the discovery
cohorts. Corresponding hazard ratios were 1.35 (95% CI, 1.01 to 1.79; P = 0.04) and 1.42 (95% CI,
1.06 to 1.91; P=0.02) in the large cohort of black persons and 1.17 (95% CI, 1.01 to 1.37; P = 0.03)
and 1.19 (95% CI, 1.01 to 1.41; P = 0.04) in the Dutch sample; the results of an underpowered analysis
of the smaller black cohort were nonsignificant.
CONCLUSIONS—A genetic locus on chromosome 12p13 is associated with an increased risk of
stroke.
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Stroke is the leading neurologic cause of death and disability.1 Twin and familial aggregation
studies suggest that the risk of stroke has a substantial genetic component,2–4 but the genes
underlying this risk in the general population remain undetermined. Studies of candidate genes
or studies that use classical linkage approaches have yielded inconsistent findings.5
Genomewide association studies have uncovered previously unsuspected common variants
underlying the risk of complex diseases such as diabetes6 and coronary disease.7,8 Two
previous genomewide association studies of stroke were limited by a case–control design that
is more susceptible to survival and selection biases than the design of prospective cohort
studies.9,10 We combined data derived from four large, prospective, population-based cohorts
consisting predominantly of white persons: the Atherosclerosis Risk in Communities (ARIC)
cohort,11 the Cardiovascular Health Study cohort,12 the Framingham Heart Study cohort,13,
14 and the Rotterdam Study cohort.15 The four cohorts are part of a consortium, the Cohorts
for Heart and Aging Research in Genomic Epidemiology (CHARGE),16 formed to generate a
discovery sample of 19,602 participants. We also present the findings from three replication
samples, a prospectively evaluated cohort of 2430 black participants in the ARIC study, a
second small, prospectively evaluated cohort of 574 black participants in the Cardiovascular
Health Study, and a case–control sample of 4265 self-reported Caucasian (hereafter called
white) Dutch persons.
METHODS
STUDY DESIGN AND SAMPLES
Details of the cohort selection and risk-factor assessment in the four studies11–15 are described
in Section 2 in the Supplementary Appendix, available with the full text of this article at
NEJM.org. The institutional review board of each study approved the study design. All
participants gave written informed consent for study participation, including genetic research.
Stroke-free participants entered the current study on the date of the blood draw used for their
genotyping, and they were followed prospectively for incident stroke. Almost all participants
in the Framingham Heart Study and Rotterdam Study described themselves as white
(Framingham Heart Study) or Caucasian (Rotterdam Study); thus, participants in the ARIC
and Cardiovascular Health Study who were black according to self-report were excluded in
our discovery analyses. Details of how ancestry was determined in the individual cohorts are
provided in Section 2 in the Supplementary Appendix. Participants were also excluded if they
did not provide informed consent or were not successfully genotyped. The analysis included
7686 participants from the ARIC study, 2022 from the Cardiovascular Health Study, 4131
from the Framingham Heart Study, and 5763 from the Rotterdam Study. Baseline demographic
and clinical characteristics of the samples are shown in Table 1.
STROKE DEFINITION, SURVEILLANCE, AND CLASSIFICATION
Stroke was defined as a focal neurologic deficit of presumed vascular cause with a sudden
onset and lasting for at least 24 hours or until death if the participant died less than 24 hours
after the onset of symptoms. Details of stroke surveillance and diagnostic criteria for stroke
and stroke types in the four studies have been published17–24 and are summarized in Section
3 in the Supplementary Appendix. Strokes were classified as ischemic, hemorrhagic, or of
“unknown” type on the basis of clinical and imaging criteria. Ischemic strokes were further
subdivided into atherothrombotic and cardioembolic subtypes. We included ischemic strokes,
hemorrhagic strokes, and strokes of unknown type in our analyses but excluded sub-arachnoid
hemorrhages.
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The consortium was formed after the individual studies had finalized their genomewide
association study platforms. In the ARIC study, genotyping was performed with the GeneChip
SNP Array 6.0 (Affymetrix); in the Cardiovascular Health Study, the HumanCNV370-Duo
(Illumina) was used; in the Framingham Heart Study, the Gene-Chip Human Mapping 500K
Array Set and 50K Human Gene Focused Panel (Affymetrix) were used; and in the Rotterdam
Study, version 3.0 of the Infinium HumanHap550 chip (Illumina) was used. All studies used
their genotype data to impute the 2.5 million autosomal single-nucleotide polymorphisms
(SNPs) using HapMap CEU as the reference population. Imputation methods and quality-
control measures are described in Section 4 in the Supplementary Appendix. We used a
TaqMan assay (Applied Biosystems) to directly genotype the SNPs reaching genomewide
significance in the combined analysis in each cohort in which the SNP had originally been
imputed.
STATISTICAL ANALYSIS
Study-Specific Analysis—Cox proportional-hazards models were used in the individual
studies to evaluate time to first stroke; participants were excluded at death or at the time of
their last follow-up examination or health status update when they were known to be stroke-
free. For the analyses of ischemic stroke, persons were also excluded when they had an
alternative type of stroke (e.g., hemorrhagic or unknown). Each study fit an additive genetic
model relating the genotype dose (0 to 2 copies of the minor allele) to the outcome (total stroke
or ischemic stroke). Primary analyses were adjusted for age and sex. In addition, the ARIC
study and the Cardiovascular Health Study adjusted the analysis for study site, and the
Framingham Heart Study adjusted the analysis for familial structure and for whether the DNA
samples had been subject to whole-genome amplification. We also adjusted the analyses
yielding the most significant associations in order to account for baseline systolic blood
pressure, hypertension (defined as systolic blood pressure ≥140 mm Hg, diastolic pressure ≥90
mm Hg, or the use of antihypertensive medications),25 and other risk factors for stroke
described in the stroke risk profile of the Framingham Heart Study: diabetes, current smoking,
and atrial fibrillation.26 Finally, we examined the association of the two SNPs that reached
genome-wide significance in our initial genomewide association study with the subtype of
atherothrombotic stroke. All studies screened for genetic variations in each population; these
variations were negligible. Additional details concerning the statistical analyses are available
in Section 5 in the Supplementary Appendix.
Combined Analysis of Study-Specific Data—We combined the results from the four
cohorts using inverse-variance weighting (fixed-effects) analysis. After verification of DNA
strands across studies and quality control, filtering, and imputation within each study, we
restricted our analysis to the 2,194,468 autosomal SNPs that were common to all studies.
Details of the analytic strategy are available in Section 6 in the Supplementary Appendix. We
decided a priori on a genomewide significance threshold of 5×10−8, which corresponds to a
target α level (P value) of 0.05 with a Bonferroni correction for 1 million independent tests.
The linkage-disequilibrium pattern seen in ongoing detailed sequencing of the genome within
European populations also provides support for the use of this threshold.27 SNPs with
5×10−8 ≤P <1×10−5 were considered to show a highly suggestive association; SNPs with
1×10−5 ≤P<1×10−4 were considered to show a moderately suggestive association.
Replication—The first replication sample comprised the black participants in the ARIC
study.11 We genotyped 2430 persons (889 men; mean [±SD] age, 53±6 years) who were
initially stroke-free and consented to genotyping. The stroke definition and surveillance
methods were identical to those used for the white participants in the ARIC study.20 We
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genotyped rs12425791 with the use of the Affy-metrix GeneChip SNP Array 6.0 and
rs11833579 (which was absent from the Affymetrix chip) by means of a TaqMan assay.
The Cardiovascular Health Study cohort included 574 black persons; genotyping of
rs11833579 and rs12425791 in these persons was undertaken at the same time as in the white
persons (with the use of a TaqMan assay). Further details on selection of the replication sample,
genotyping quality-control filters, and analyses are outlined in Section 7 in the Supplementary
Appendix.
We carried out a third test of replication in a sample of 652 white Dutch persons with prevalent
stroke (313 women; mean age, 77±7 years; 501 ischemic strokes, of which 400 were
atherothrombotic) and age-matched controls. We genotyped rs12425791 and rs11833579 in
persons with prevalent stroke in the Rotterdam Study at baseline, in a clinical series from three
hospitals in the Netherlands, and in controls selected from among Rotterdam Study participants
who were stroke-free at baseline and within the same age range as the persons with stroke. We
genotyped both SNPs with the use of the TaqMan system. Inclusion and exclusion criteria for
the replication samples were the same as these used for the discovery samples.
RESULTS
We observed 1544 incident strokes (1164 ischemic strokes) among 19,602 persons followed
for an average of 11 years (Table 1). Figures 1A and 1B show the results of the genomewide
association study for total and ischemic stroke. For highly suggestive loci with P<1×10−5, the
hazard ratios and population attributable risks associated with the minor allele are shown in
Table 2; results for all associated SNPs, including moderately suggestive loci with
P<1×10−4, are shown in Tables 1 and 2 in the Supplementary Appendix. The full set of results
can be obtained at the European Genotype Archive (www.ebi.ac.uk/ega; accession number,
EGA00000000060).
P values for two SNPs located on chromosome 12p13 (rs11833579 and rs12425791) surpassed
our preset threshold (P = 5×10−8) for genomewide significance both for total stroke and for
ischemic stroke (Table 2, and Tables 1 and 2 in the Supplementary Appendix). The hazard
ratios were larger and the P values were smaller for the association of these two SNPs with the
more specific phenotype of ischemic stroke than for the association with total stroke, despite
a smaller number of ischemic stroke events. Results of the initial genomewide association study
suggested that each copy of a minor allele at these two loci increased the hazard ratio for total
stroke by 1.31 to 1.32 (95% confidence interval [CI], 1.19 to 1.44) and for ischemic stroke by
1.39 to 1.41 (95% CI. 1.27 to 1.56). The corresponding population attributable risks were 11
to 13% for total stroke and 14 to 17% for ischemic stroke. We found no association between
rs11833579 and rs12425791 and nonischemic stroke (hazard ratio, 1.13; 95% CI, 0.94 to 1.36;
P = 0.20 for each SNP). The risk estimates for both SNPs were similar across the four studies,
as shown by a Forest plot (Fig. 2 in the Supplementary Appendix). We also observed an
association of rs11833579 and rs12425791 with ischemic stroke when we used genotypes
obtained by means of a TaqMan assay.
We tested for an association between the two implicated SNPs and the atherothrombotic
subtype of ischemic stroke, and we observed associations that were stronger than those of the
two SNPs with all ischemic strokes. Thus, for rs11833579 hazard ratios were 1.26 (95% CI,
1.16 to 1.37) for total stroke, 1.33 (95% CI, 1.21 to 1.47) for ischemic stroke, and 1.35 (95%
CI, 1.21 to 1.50) for atherothrombotic stroke. Hazard ratios for rs12425791 were 1.30 (95%
CI, 1.19 to 1.42) for total stroke, 1.33 (95% CI, 1.21 to 1.47) for ischemic stroke, and 1.37
(95% CI, 1.23 to 1.54) for atherothrombotic stroke (Fig. 2).
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Both SNPs were in close proximity to NINJ2, which encodes ninjurin2, and they were in
significant linkage disequilibrium with each other (r2 = 0.73 based on HapMap CEU data,
National Center for Biotechnology Information [NCBI] build 36) and with SNPs in the 5′
untranslated region of NINJ2 (Fig. 3 in the Supplementary Appendix). Figure 3 shows all SNPs
within a 200-kb region on either side of these two SNPs, together with the recombination rates
and the known genes in that region. Two other SNPs that were also close to the 5′ end of
NINJ2 (rs7298096 and rs7297967) showed a strong, albeit not significant, association with
both total and ischemic stroke at P values of less than 5×10−5 (Table 2, and Tables 1 and 2 in
the Supplementary Appendix). In addition, several other SNPs within NINJ2 showed a modest
association (P<0.01) with both phenotypes (13 SNPs showed a modest association with total
stroke, and 10 SNPs with ischemic stroke).
The second closest gene to rs12425791 and rs11833579 is WNK1, although it is separated from
these SNPs by a putative recombination hot spot. This gene encodes the lysine-deficient protein
kinase 1. WNK1 has been related to blood-pressure levels and to the severity of hypertension
in a general population.29,30 Adjusting the analyses for systolic blood pressure, hypertension,
diabetes, atrial fibrillation, and current smoking individually or together had negligible effects
on the observed associations (Table 3 in the Supplementary Appendix).
We observed a replication of the association between rs12425791 and stroke in the black
participants in the ARIC study. Over a follow-up period of 15 years, 215 persons had an incident
stroke (191 strokes were ischemic; of these, 153 were atherothrombotic). With a minor-allele
frequency of 10% in this sample, rs12425791 was associated with incident total stroke (hazard
ratio, 1.35; 95% CI, 1.01 to 1.79; P = 0.04), ischemic stroke (hazard ratio, 1.42; 95% CI, 1.06
to 1.92; P = 0.02), and atherothrombotic stroke (hazard ratio, 1.41; 95% CI, 1.01 to 1.95; P =
0.04). We observed no association between rs11833579 and stroke, probably because of the
low linkage disequilibrium (r2 = 0.35) between the two SNPs in this sample. Our tests of
association in the small sample of black persons in the Cardiovascular Heart Study, which
included only 68 persons with incident ischemic strokes, did not provide evidence of
replication. This sample had 21% power to detect a 30% increase in risk at an alpha level of
0.05.
In the Dutch case–control sample, we observed replication of the association of rs12425791
with total stroke (odds ratio, 1.17; 95% CI, 1.01 to 1.37; P = 0.03), ischemic stroke (odds ratio,
1.19; 95% CI, 1.01 to 1.41; P = 0.04), and atherothrombotic stroke (odds ratio, 1.29; 95% CI,
1.08 to 1.54; P = 0.005) and replication of the association of rs11833579 with the prevalence
of atherothrombotic stroke (odds ratio,1.19; 95% CI, 1.00 to 1.40; P = 0.05).
A combined analysis of the discovery and replication samples of white subjects yielded, for
rs12425791, an overall hazard ratio for the risk of ischemic stroke of 1.29 (95% CI, 1.19 to
1.41; P=1.1×10−9) (Table 5 in the Supplementary Appendix). We observed highly suggestive
associations (which were not significant at a genome-wide level) with both the total stroke and
ischemic stroke phenotypes (in 4 SNPs), with total stroke only (in 71 SNPs) and with ischemic
stroke only (in 13 SNPs) (Table 2). We also examined associations with candidate SNPs
previously reported to be significantly associated with either total or ischemic stroke (Section
8 and Table 6 in the Supplementary Appendix).
DISCUSSION
In this combined analysis of genomewide association study data from four large cohort studies
of incident stroke, two previously unsuspected common SNPs on chromosome 12p13 were
consistently associated with total, ischemic, and atherothrombotic stroke in white persons. We
observed a replication of one of these SNPs in two independent samples: North American black
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persons and Dutch white persons. We did not observe a replication of the association of either
SNP with stroke in a second, smaller sample of North American blacks.
We had a priori considered total stroke, a heterogeneous phenotype, as our primary outcome.
However, the stronger association with ischemic and atherothrombotic strokes (as compared
with total stroke) and the absence of any association with nonischemic stroke indicate that
rs11833579 and rs12425791 were specifically associated with ischemic stroke and, in
particular, the atherothrombotic stroke subtype. The effect sizes were similar when we tested
for an association using directly genotyped (rather than imputed) SNPs, and the estimated
hazard ratios for incident stroke were similar in all four discovery cohorts and in the black
replication sample from the ARIC cohort.
Ninjurin2 is one of two transmembrane proteins in the ninjurin, or “nerve-injury-induced
protein” family, and it has invertebrate homologues in the genomes of anopheles and drosophila
species. It is a homophilic cell–cell adhesion molecule that interacts with matrix
metalloproteinases.31 In the peripheral nervous system of male Sprague-Dawley rats, ninjurin
is inducible in Schwann cells and dorsal-root ganglia through nerve injury, is transported from
the perikaryon to the axon, and promotes neurite extension resulting in nerve regeneration.32
In the central nervous system, it is constitutively expressed at low levels by radial glia.32
Microarray studies have shown differences in the expression of ninjurin2 within the spinal cord
of Nogo-A–specific knockout mice (in which neurites are increased by a factor of two to four
after injury) as compared with wild-type controls.33 It is possible that the level of expression
of ninjurin2 affects how the brain tolerates ischemic insults.
Wnk1 is expressed in the developing nervous system and in the aorta and brain vasculature of
the mouse.34 WNK1 regulates the transport of sodium, potassium, and chloride ions across the
plasma membrane.35,36 It phosphorylates the protein synaptotagmin, which results in an
increased calcium requirement for synaptotagmin to bind to phospholipid vesicles, a process
facilitating vesicle fusion.37 WNK1 mutations have been linked to familial hyperkalemic
hypertension,35 to elevated ambulatory blood pressures in a community sample,29 and to the
severity of essential hypertension.30 Although hypertension is a major risk factor for stroke,
38 we did not observe a change in the strength of association between SNPs (rs11833579 or
rs12425791) adjacent to WNK1 and stroke, after adjusting for systolic blood pressure or
hypertension, suggesting that the role of WNK1 in regulating blood pressure does not explain
the genetic associations we report here.
A recent genomewide association study of stroke cases and controls did not detect the
NINJ2 signal.10 However, this study used a platform that does not genotype either rs11833579
or rs12425791 and has no proxy SNPs in moderate or significant linkage disequilibrium
(r2≥0.4) with these two SNPs.
Our study has limitations. The identified intergenic SNPs are probably not the causal variants;
it is more likely that they are in linkage disequilibrium with the causal variants. Further
exploration of this genomic region with more detailed genotyping, expression, and translational
studies will be required. There were too few events to study genotype–phenotype associations
underlying individual subtypes of atherothrombotic stroke, such as cortical or lacunar ischemic
strokes. Finally, we had limited power to detect associations with small effect sizes and
associations with rare variants. Nonetheless, our analysis of genomewide association study
data from four large community-based studies has identified a previously unsuspected
association with incident stroke.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Results of Tests for the Association between Stroke and Each SNP Measured in the
Genomewide Association Study
P values (based on the fixed-effects model) are shown in signal-intensity (Manhattan) plots
relative to their genomic position for total stroke (Panel A) and ischemic stroke (Panel B).
Within each chromosome, the results are plotted left to right from the p-terminal end. The top
horizontal line indicates the chosen threshold for genomewide significance, P = 5×10−8; the
middle line indicates the threshold for P = 10−5; and the bottom line indicates the threshold for
P = 10−4.
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Figure 2. Forest Plots Showing Associations between Single-Nucleotide Polymorphisms and Total,
Ischemic, and Atherothrombotic Strokes
The associations between rs11833579 and total stroke (Panel A), ischemic stroke (Panel C),
and atherothrombotic stroke (Panel E) and between rs12425791 and total stroke (Panel B),
ischemic stroke (Panel D), and atherothrombotic stroke (Panel F) are based on directly
genotyped data. Individual studies (blue boxes) are plotted against the individual effect sizes
(hazard ratios). The red diamonds indicate the overall hazard ratios. The size of the blue box
is inversely proportional to the variance. Horizontal lines indicate 95% confidence intervals.
The dashed vertical line in each panel shows the value for no effect (hazard ratio = 1.0). ARIC
denotes Atherosclerosis Risk in Communities study, CHS Cardiovascular Health Study, FHS
Framingham Heart Study, and RS Rotterdam Study.
Ikram et al. Page 11













Figure 3. Associations in the Region Centered on rs11833579 and Containing NINJ2
All single-nucleotide polymorphisms are plotted with their P values (on combined analysis)
against their genomic position. P values for total stroke and ischemic stroke are shown. The
light blue line represents the estimated recombination rates. Blue arrows indicate gene
annotations.
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Table 1
Characteristics of the Study Population in the Discovery Cohorts for Analysis of Incident Total Stroke and
Incident Ischemic Stroke.*
Variable ARIC (N = 7686)CHS (N = 2022)FHS (N = 4131)Rotterdam (N = 5763)
Female sex (%) 53 55 55 59
Mean follow-up (yr) 15 11 6 10
Mean age (yr)
 At DNA draw 54±6 73±6 66±12 69±9
 At incident stroke 66±7 81±6 80±10 80±8
Strokes (no.)
 Prevalent 12 0‡ 135 170
 Incident total 312 459 156 617
 Incident ischemic 277 389 131 367
 Incident atherothrombotic 243 264 82 296
Cardiovascular risk factors at baseline†
 Systolic blood pressure (mm Hg) 118±17 138±22 131±20 139±22
 Diastolic blood pressure (mm Hg) 72±10 71±11 74±10 74±12
 Hypertension (%) 27 61 52 61
 Diabetes mellitus (%) 6 14 12 10
 Current smoker (%) 25 11 14 23
 Prevalent cardiovascular disease other than stroke (%) 5 0‡ 16 10
*
Plus–minus values are means ±SD. Sample numbers include only genotyped persons who also provided consent for these analyses and had high-quality
genotyping (i.e., that met quality-control criteria). ARIC denotes Atherosclerosis Risk in Communities, CHS Cardiovascular Health Study, and FHS
Framingham Heart Study.
†
The definition of baseline risk factors was uniform in all four studies. Hypertension was defined with the use of criteria from the seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: systolic blood pressure of 140 mm Hg or more,
diastolic blood pressure of 90 mm Hg or more, or the use of an antihypertensive agent. Diabetes mellitus was defined as a blood glucose level of 200 mg
per deciliter (11 mmol per liter) or more in a random or 2-hour postprandial specimen, a fasting blood glucose level of 126 mg per deciliter (7 mmol per
liter) or more, or the use of insulin or oral hypoglycemic agents. Cardiovascular disease was defined as the presence of congestive heart failure, coronary
heart disease, or intermittent claudication.
‡
In the CHS, persons with prevalent stroke or other cardiovascular disease were not genotyped.
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